ALK-Abelló company profile
Company profile
ALK-Abelló has 2,773 employees and is headquartered in Horsholm, Denmark.
GRAZAX, ACARIZAX, ODACTRA and RAGWITEK are among the allergy immunotherapy tablets that ALK-Abelló offers for grass pollen, house dust mite and ragweed allergies, while its adrenaline autoinjectors and nasal sprays are used for emergency treatment of anaphylaxis. The portfolio also includes vaccines, injections and sublingual drops for respiratory allergies, a biologic for food allergies called ALK 014, the klarify.me patient engagement platform and allergen extracts used in diagnosis. Its treatments address respiratory allergy, anaphylaxis and food allergy, with activity in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan and China. Development work includes collaborations with Torii Pharmaceutical for GRAZAX and CEDARCURE and with Dr. Reddy's Laboratories for Sensimune.
In the fiscal year ended 31 December 2025, ALK-Abelló reported revenue of DKK 6.3 billion, up 14.0% on the previous year, and net income of DKK 1.2 billion. Founded in 1923, the company is headquartered in Horsholm, Denmark, and had 2,773 employees.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Headquarters
- Bøge Allé 6-8, 2970, Horsholm
- Employees
- 2,773
- Chief executive
- Peter Halling
- Founded
- 1923
- Fiscal year
- January - December
- Listing
- ALK.B · Nasdaq Copenhagen
- Currency
- DKK
- ISIN
- DK0061802139
- Website
- alk.net
ALK-Abelló and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| ALK-AbellóALK.B | Denmark | $8.09B | 2,773 | 26.9% | 40.7 |
| ABIVAXABVX | France | $7.61B | 98 | -6,270.4% | — |
| Bachem HoldingBANB | Switzerland | $6.92B | 2,725 | 21.8% | 39.2 |
| Financière de TubizeTUB | Belgium | $11.78B | 3 | 0.0% | 109.0 |
| CamurusCAMX | Sweden | $4.36B | 323 | 37.4% | 58.5 |
| BioArcticBIOA.B | Sweden | $2.72B | 150 | 19.6% | 262.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
